Literature DB >> 16394626

Increase in tumor oxygenation and potentiation of radiation effects using pentoxifylline, vinpocetine and ticlopidine hydrochloride.

Morikazu Amano1, Hajime Monzen, Minoru Suzuki, Kaoru Terai, Satoshi Andoh, Akio Tsumuraya, Takeo Hasegawa.   

Abstract

The purpose of the present study was to investigate the effects of Pentoxifylline (PTX), Vinpocetine (VPT) and Ticlopidine Hydrochloride (TCD), used commonly for vascular disorders in humans, on the pO2 in SCCVII tumors of C3H/HeJ mice and on the radioresponse of SCCVII tumors. The pO2 in the SCCVII tumors, which were measured 30 min after intraperitoneal (i.p.) injection of PTX (5 mg/kg), VPT (5 mg/kg), or TCD (10 mg/kg) using polarography, was compared to that in saline-treated control tumors. All the three drugs, PTX, VPT and TCD, yielded significant increase of the pO2 in the SCCVII tumors from 25.6 to 26.9 mmHg, from 18.6 to 22.9 mmHg, and from 22.6 to 25.9 mmHg, respectively. Frequency histogram of the pO2 distribution in the saline-treated SCCVII tumors did not show hypoxic fraction of less than 10 mmHg. The radioresponses of the drugs were investigated by tumor growth delay assay. In the drug-treated groups, the SCCVII tumors were irradiated with a single dose of 15 Gy 30 min after injection of the drugs at the same doses as those used in the experiments for intratumoral pO2 measurement. Compared with the irradiation alone group, significant tumor growth delays were observed in all the drug-treated groups. The time required to reach a four-fold increase in the initial tumor volume were 4 days in the saline-treated control group, 22 days in the irradiation (IR) alone group, 28 days in the PTX + IR group, 29 days in the VPT + IR group, and 32 days in TCD + IR group. In conclusion, VPT and TCD are potentially promising drugs for increasing the intratumoral pO2 although the mechanism for radiopotentiation observed in the present study is unknown due to small hypoxic fraction in the SCCVII tumors. Further studies on other mechanisms for radiopotentiation of PTX, VPT or TCD, besides of increasing the pO2 in the tumor, are needed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16394626     DOI: 10.1269/jrr.46.373

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  4 in total

1.  Letter to editor. Re: "Effect of concomitant use of pentoxifylline (PTX) and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer".

Authors:  Lucy Jellett; Claire Harrison; Jonathan McAleese
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 2.  Mechanisms of radiation-induced endothelium damage: Emerging models and technologies.

Authors:  Harshani Wijerathne; Jordan C Langston; Qingliang Yang; Shuang Sun; Curtis Miyamoto; Laurie E Kilpatrick; Mohammad F Kiani
Journal:  Radiother Oncol       Date:  2021-02-11       Impact factor: 6.280

3.  Synergistic radioprotection by gamma-tocotrienol and pentoxifylline: role of cAMP signaling.

Authors:  Shilpa Kulkarni; Kushal Chakraborty; K Sree Kumar; Tzu-Cheg Kao; Martin Hauer-Jensen; Sanchita P Ghosh
Journal:  ISRN Radiol       Date:  2013-07-07

Review 4.  Pharmacological potential of tocotrienols: a review.

Authors:  Haseeb Ahsan; Amjid Ahad; Jahangir Iqbal; Waseem A Siddiqui
Journal:  Nutr Metab (Lond)       Date:  2014-11-12       Impact factor: 4.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.